164 related articles for article (PubMed ID: 37339995)
1. Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors.
Berry MA; Bland AR; Ashton JC
Sci Rep; 2023 Jun; 13(1):10041. PubMed ID: 37339995
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer.
Shrestha N; Nimick M; Dass P; Rosengren RJ; Ashton JC
Sci Rep; 2019 Dec; 9(1):18842. PubMed ID: 31827192
[TBL] [Abstract][Full Text] [Related]
3. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
[TBL] [Abstract][Full Text] [Related]
4. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
[TBL] [Abstract][Full Text] [Related]
5. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
[No Abstract] [Full Text] [Related]
6. Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors.
Wu H; Zeng C; Ye Y; Liu J; Mu Z; Xie Y; Chen B; Nong Q; Wu D
Mol Pharm; 2018 May; 15(5):1892-1900. PubMed ID: 29595984
[TBL] [Abstract][Full Text] [Related]
7. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
Kim D; Koh Y; Yoon SS
Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
[TBL] [Abstract][Full Text] [Related]
10. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer.
Bland AR; Bower RL; Nimick M; Hawkins BC; Rosengren RJ; Ashton JC
Eur J Pharmacol; 2019 Dec; 865():172749. PubMed ID: 31654622
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC.
Xiao J; Zhang L; Yi H; Zou L; Mo J; Xue F; Zheng J; Huang Y; Lu H; Wu H; Xue P; Zhang X; He L; Li Z; Pang S; Qiao G; Duan Q; Zhu F
Cell Death Dis; 2022 Sep; 13(9):828. PubMed ID: 36167821
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer.
Shrestha N; Bland AR; Bower RL; Rosengren RJ; Ashton JC
J Pharmacol Exp Ther; 2020 Jul; 374(1):134-140. PubMed ID: 32284325
[TBL] [Abstract][Full Text] [Related]
14. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract][Full Text] [Related]
15. Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.
Yang L; Li G; Zhao L; Pan F; Qiang J; Han S
Tumour Biol; 2014 Oct; 35(10):9759-67. PubMed ID: 24972969
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
17. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
Tani T; Yasuda H; Hamamoto J; Kuroda A; Arai D; Ishioka K; Ohgino K; Miyawaki M; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Ther; 2016 Jan; 15(1):162-71. PubMed ID: 26682573
[TBL] [Abstract][Full Text] [Related]
18. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
Tsuji T; Ozasa H; Aoki W; Aburaya S; Funazo T; Furugaki K; Yoshimura Y; Ajimizu H; Okutani R; Yasuda Y; Nomizo T; Uemasu K; Hasegawa K; Yoshida H; Yagi Y; Nagai H; Sakamori Y; Ueda M; Hirai T; Kim YH
Mol Cancer Res; 2019 Jan; 17(1):212-224. PubMed ID: 30171175
[TBL] [Abstract][Full Text] [Related]
19. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
[No Abstract] [Full Text] [Related]
20. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
